Pediatric Oncology and Hematology Unit, La Fe University Hospital, Valencia, Spain.
Pediatric Oncology Unit, Regional University Hospital of Malaga, Málaga, Spain.
Target Oncol. 2023 Jan;18(1):77-93. doi: 10.1007/s11523-022-00930-w. Epub 2022 Dec 12.
The anti-GD2 antibody dinutuximab beta (Qarziba) has been added to the present standard of care for patients with high-risk neuroblastoma in Europe based on the positive results obtained in different studies. In both the first-line and relapsed/refractory settings, treatment with dinutuximab beta attains objective clinical responses in children with high-risk neuroblastoma. Its incorporation has changed the outcome for these patients and optimized management should be guaranteed to minimize possible adverse effects. Most prevalent adverse events include pain, allergic reactions, fever and capillary leak syndrome. There are still no evidence-based clinical guidelines that include the latest published evidence to optimize its use, as it depends on the experience gained in each referral center. Topics such as the mode of preparation and administration, the concomitant use of interleukin-2, the recommended pediatric age and dose for its use, or the adequate management of possible toxicities are important aspects to review. The objective of this article was to update the clinical guide to management with dinutuximab beta of children with neuroblastoma based on the most recent published evidence and our own experience in clinical practice.
抗 GD2 抗体 dinutuximab beta（Qarziba）已根据不同研究的阳性结果，被添加到欧洲高危神经母细胞瘤患者的现行标准治疗方案中。在一线和复发/难治性治疗环境中，dinutuximab beta 治疗高危神经母细胞瘤儿童可获得客观的临床反应。它的加入改变了这些患者的结局，应保证优化管理以尽量减少可能的不良反应。最常见的不良反应包括疼痛、过敏反应、发热和毛细血管渗漏综合征。目前还没有包括最新发表的证据的循证临床指南来优化其使用，因为它取决于每个转诊中心获得的经验。诸如准备和给药方式、白细胞介素-2 的联合使用、推荐的儿科年龄和剂量、或可能毒性的适当管理等方面都是需要审查的重要内容。本文的目的是根据最新发表的证据和我们在临床实践中的经验，更新高危神经母细胞瘤儿童使用 dinutuximab beta 的临床管理指南。
